PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in "real-world"...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | ספר |
| יצא לאור: |
Столичная издательская компания,
2015-12-01T00:00:00Z.
|
| נושאים: | |
| גישה מקוונת: | Connect to this object online. |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|